MedTrace Logo

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

NCT00506077 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2015-08-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.

Conditions

  • Paranoid Schizophrenia

Interventions

DRUG

MK0249

MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.

DRUG

Comparator: Placebo (unspecified)

MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-10-31
Completion
2008-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00506077 on ClinicalTrials.gov